Document Detail

Reduced sulphoxidation capacity in D-penicillamine induced myasthenia gravis.
MedLine Citation:
PMID:  7835005     Owner:  NLM     Status:  MEDLINE    
Myasthenia gravis may be observed due to treatment with penicillamine (D-PA). The sulphoxidation capacity was measured in nine Swedish patients with rheumatoid arthritis (RA) who had developed myasthenia gravis toward D-PA. The results show that in eight of nine patients tested, this parameter was markedly reduced. A patient with poor sulphoxidation capacity has a twelve-fold greater risk of developing this rare side effect. The significance of this is discussed.
P Seideman; R Ayesh
Related Documents :
786115 - The role of humoral and cellular immune factors in neuromuscular block in myasthenia gr...
22609385 - Increased risk for persistent intestinal metaplasia in patients with barrett's esophagu...
7835005 - Reduced sulphoxidation capacity in d-penicillamine induced myasthenia gravis.
18650185 - Association between renal cell carcinoma and plasma cell dyscrasias: a case series of s...
12394905 - Changes in scoliotic curvature and lordotic angle during the early phase of degenerativ...
25181915 - Serum fetuin-a levels in patients with systolic heart failure.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical rheumatology     Volume:  13     ISSN:  0770-3198     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-03-02     Completed Date:  1995-03-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  BELGIUM    
Other Details:
Languages:  eng     Pagination:  435-7     Citation Subset:  IM    
Department of Internal Medicine, Karolinska Institute, Danderyd, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / drug therapy*,  metabolism
Middle Aged
Myasthenia Gravis / chemically induced*,  urine
Penicillamine / adverse effects*,  metabolism,  therapeutic use
Sulfoxides / metabolism*,  urine
Reg. No./Substance:
0/Sulfoxides; 52-67-5/Penicillamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical correlation of anticentromere antibodies.
Next Document:  Sjogren's syndrome in Israel: primary versus secondary disease.